

Box Seg.

PATENT Docket No. 041673/2007

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL

Date of Deposit: July 20, 2000

I hereby certify that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, <u>Washington D.C.</u> 20231.

Angela Bernal

Printed Name

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Ethan Bier, Kweon Yu.

Serial No.: 09/215,569

Filing Date: December 16, 1998

For: PEPTIDE INHIBITOR OF TGF-BETA

GROWTH FACTORS

Examiner: Romeo, D.

Group Art Unit: 1646

TRANSMITTAL

Box Sequence Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Enclosed please find the following:

- [X] Response to Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 Pages)
- [X] Copy of Notice to Comply (1 Page)
- [X] Computer Disk Containing Sequence Listing (1 Disk)
- [X] Return postcard

The Assistant Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.21 that may be required by this transmittal, or to credit any overpayment, to **Deposit Account No. 50-0872**.

Respectfully submitted,

Date

FOLEY & LARDNER 402 West Broadway

23rd Floor

San Diego, California 92101-3542

Telephone:

(619) 685-6432

7-19-2000

Facsimile:

(619) 234-3510

ву_

Stacy L. Taylor

Attorney for Applicant Registration No. 34,842



PATENT Docket No. 041673/2007

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL

Date of Deposit: July 20, 2000

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on

the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington D.C. 20231.

Angela K Bernal

Printed Name

Signature

#9 8/8/OT Bray

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Ethan Bier, Kweon Yu

Serial No.: 09/215.569

Filing Date: December 16, 1998

For: PEPTIDE INHIBITOR OF TGF-BETA

GROWTH FACTORS

Examiner: Romeo D.

Group Art Unit: 1646

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Box Sequence Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Notice to comply with Requirements for Applications containing Sequence Disclosures mailed June 20, 2000, the errors pointed out in the office action were corrected on the disk copy as requested:

Line <160> NUMBER OF SEQ ID NOS: deleted "13" added "12".

Line <400> SEQUENCE: 1: deleted tab codes so that "879" is in appropriate place.

Only the changes identified in the Office Action were made, the rest of the disk remained as previously submitted.

In connection with the Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

- 1. the content of the previously submitted paper copy and the enclosed computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and
- 2. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter.

Remarks

In the unlikely event that the transmittal letter is separated from this sequence listing and the U.S. Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this sequence listing to our **Deposit Account No. 50-0872**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

By

Respectfully submitted,

Stacy L. Taylor

Attorney for Applicant Registration No. 34,842

FOLEY & LARDNER 402 West Broadway

23rd Floor San Diego, California 92101-3542

Telephone:

(619) 685-6432

Facsimile: (6

(619) 234-3510

Serial No. 09/215,569

Docket No. 041673/2007

Application No.: 09215569

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING \ NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

×	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
×	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Applicant Must Provide:	
×	A n initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
×	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Foi	questions regarding compliance to these requirements, please contact:
	Rules Interpretation, call (703) 308-4216
	r CRF Submission Help, call (703) 308-4212 tentIn Software Program Support (SIRA)
	Technical Assistance703-287-0200
	To Purchase Patentin Software 703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE